Christer Halldin

Q: What Schools Are Affiliated With Christer Halldin

Christer Halldin is affiliated with the following schools: Stockholm University, Uppsala University, Lund University, Nanyang Technological University, Karolinska Institute

Christer Halldin's AcademicInfluence.com Rankings

Christer Halldin

Chemistry

#1965

World Rank

#2795

Historical Rank

chemistry Degrees

Christer Halldin

Biology

#5654

World Rank

#8188

Historical Rank

Biotechnology

#41

World Rank

#42

Historical Rank

Molecular Biology

#522

World Rank

#535

Historical Rank

Genetics

#517

World Rank

#593

Historical Rank

biology Degrees

Download Badge

Chemistry
Biology

Christer Halldin's Degrees

PhD Biomedical Sciences Uppsala University
Masters Biotechnology Stockholm University
Bachelors Chemistry Lund University

Why Is Christer Halldin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christer Halldin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The gut microbiota influences blood-brain barrier permeability in mice (2014) (1387)
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. (1992) (1360)
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. (1988) (663)
Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients (1993) (518)
A PET study of (2000) (515)
D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. (1990) (515)
Age-related cognitive deficits mediated by changes in the striatal dopamine system. (2000) (469)
Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis (1989) (463)
Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain (1994) (399)
D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. (1995) (340)
Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain (2004) (319)
No D2 receptor increase in PET study of schizophrenia. (1987) (297)
Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 (1997) (287)
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. (1999) (253)
The role of the striatal dopamine transporter in cognitive aging (2005) (251)
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. (1997) (246)
Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. (1983) (231)
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. (2006) (230)
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. (1995) (229)
Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity (2005) (228)
Synthesis of L- and D-[methyl-11C]methionine. (1987) (213)
Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET (2008) (207)
Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. (2002) (200)
Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand (2012) (193)
Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) (189)
A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients (1997) (188)
Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain (1994) (181)
Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. (1986) (174)
Imaging the Function of P‐Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications (2009) (174)
PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. (2002) (173)
Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain (1999) (173)
Variability in D2‐dopamine receptor density and affinity: A PET study with [11C]raclopride in man (1995) (173)
Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy (2004) (172)
Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride (1996) (169)
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-l-deprenyl using whole hemisphere autoradiography (2011) (168)
Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding (1998) (167)
Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation (2019) (159)
Positron Emission Tomography Studies on D2 and 5‐HT2 Receptor Binding in Risperidone‐Treated Schizophrenic Patients (1995) (158)
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). (2011) (157)
Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility (2000) (154)
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. (2015) (154)
PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride (2004) (150)
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. (1995) (146)
No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone (1995) (145)
A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects (1997) (138)
Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites--current status. (1993) (136)
PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. (1998) (134)
Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. (1998) (133)
Turnover of Brain Monoamine Oxidase Measured In Vivo by Positron Emission Tomography Using l‐[11C]Deprenyl (1987) (130)
Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I (1999) (129)
Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. (1998) (128)
Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. (1985) (126)
Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907 (1996) (126)
Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. (2004) (125)
Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. (2003) (121)
PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain (2004) (119)
Brain radioligands--state of the art and new trends. (2001) (118)
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease (2000) (116)
Autoradiographic localization of 5‐HT2A receptors in the human brain using [3H]M100907 and [11C]M100907 (2000) (115)
Performance Evaluation of the Small-Animal nanoScan PET/MRI System (2013) (115)
Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride (2006) (114)
Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain (1997) (112)
New PET radiopharmaceuticals beyond FDG for brain tumor imaging. (2012) (112)
EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues (2006) (110)
Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans. (2009) (110)
Effects of chronic 17β‐estradiol treatment on the serotonin 5‐HT1A receptor mRNA and binding levels in the rat brain (2000) (109)
Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand (11C)raclopride from (11C)methyl triflate (1999) (107)
PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 (1998) (106)
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease (2019) (105)
Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. (1999) (104)
Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects (2015) (103)
Comparison of the In Vitro Receptor Binding Properties of N‐[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes (1990) (102)
No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. (2001) (101)
PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. (2001) (101)
Molecular Imaging of the Dopamine Transporter (2010) (101)
Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28 (2017) (100)
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study (2015) (100)
Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET (2004) (99)
Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. (2005) (99)
Improved synthesis of some commonly used PET radioligands by the use of [11C]methyl triflate. (1995) (98)
Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU (2008) (98)
Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET (2004) (97)
[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. (1996) (96)
PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor (2005) (96)
Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography (1989) (94)
A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria (2006) (94)
Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. (1998) (93)
Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. (1989) (93)
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand (2009) (93)
Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol (2005) (93)
5-HT2 and D2 dopamine receptor occupancy in the living human brain (1993) (91)
D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. (1994) (90)
Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique. (1999) (88)
Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. (1996) (88)
[11C] beta-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. (1993) (87)
Radioligand Disposition and Metabolism — Key Information in Early Drug Development (1995) (87)
Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects (2012) (85)
A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. (2005) (85)
Age and disease related changes in the translocator protein (TSPO) system in the human brain: Positron emission tomography measurements with [11C]vinpocetine (2011) (85)
Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184 (2009) (85)
Changes in striatal D2‐receptor density following chronic treatment with amphetamine as assessed with pet in nonhuman primates (1999) (84)
Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands (2010) (84)
[11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain (2003) (82)
The immune response of the human brain to abdominal surgery (2017) (82)
Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains (2017) (82)
Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models (2016) (81)
11C-labelling of Ro 15-1788 in two different positions, and also 11C-labelling of its main metabolite Ro 15-3890, for PET studies of benzodiazepine receptors. (1988) (80)
[11C]β‐CIT‐FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography (1996) (79)
The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain (2008) (79)
[11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain (2008) (79)
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. (2003) (77)
Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum (2008) (77)
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106 (2013) (77)
The synthesis of 1-11C-labelled ethyl, propyl, butyl and isobutyl iodides and examples of alkylation reactions (1986) (77)
D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model (2010) (77)
Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. (2013) (77)
Whole hemisphere autoradiography of the postmortem human brain. (1998) (76)
Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I (2012) (76)
PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain (1997) (76)
European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. (2002) (75)
Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man (1995) (74)
PET analysis of central [11 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effects (1992) (74)
Distribution of 5-HT4 receptors in the postmortem human brain—an autoradiographic study using [125I]SB 207710 (2003) (74)
Quantitative Analysis of [11C]AZ10419369 Binding to 5-HT1B Receptors in Human Brain (2011) (74)
Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. (2005) (74)
Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: Preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients (2008) (74)
Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography (1997) (74)
A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system (2009) (74)
Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography (2006) (74)
Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: A PET study with the TSPO molecular imaging biomarker [ 11 C]vinpocetine (2012) (73)
Methylation of amide and thiol functions with [11C]methyl triflate, as exemplified by [11C]NMSP[11C]flumazenil and [11C]methionine (1998) (73)
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. (2015) (73)
5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects (2013) (72)
A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques (2014) (72)
A PET study of D2 dopamine receptor density at different phases of the menstrual cycle (1998) (71)
[11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET (2005) (71)
Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer’s disease patients and control subjects (2015) (71)
European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc-labelled radiopharmaceuticals. (2002) (70)
Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. (2005) (70)
Nigrostriatal dopamine transporter availability in early Parkinson's disease (2018) (70)
In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients (2013) (70)
PET and SPET tracers for mapping the cardiac nervous system (2002) (69)
Reproducibility of [11C]FLB 457 binding in extrastriatal regions (2001) (69)
Palladium-Mediated [11C]Carbonylation at Atmospheric Pressure: A General Method Using Xantphos as Supporting Ligand (2013) (69)
[18F]Flumazenil binding to central benzodiazepine receptor studies by PET – Quantitative analysis and comparisons with [11C]flumazenil – (2009) (69)
Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility (2008) (68)
Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study (2006) (68)
A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. (1991) (68)
Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging. (2008) (68)
Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter (2001) (67)
PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects (2002) (67)
The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: A post-mortem autoradiographic study (2010) (67)
[O-methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. (1995) (66)
PET Mapping of Extrastriatal D2-like Dopamine Receptors in the Human Brain Using an Anatomic Standardization Technique and [11C]FLB 457 (1999) (66)
(S)- and (R)-[11C]nicotine and the metabolite (R/S)-[11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. (1992) (65)
New methodologies for the preparation of carbon-11 labeled radiopharmaceuticals (2017) (64)
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2 (2006) (64)
Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs (1996) (63)
European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. (2002) (63)
Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2 (2005) (62)
Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study (2010) (62)
Selective, irreversible in vivo binding of [11C]clorgyline and [11C]-L-deprenyl in mice: potential for measurement of functional monoamine oxidase activity in brain using positron emission tomography. (1985) (62)
Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study (2000) (62)
Quantitative localization of human brain monoamine oxidase B by large section autoradiography using l-[3H]deprenyl (1991) (61)
A PET study of D1-like dopamine receptor ligand binding (1999) (61)
Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy (2008) (61)
In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. (2010) (60)
In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE‐PE2I, a new dopamine transporter PET radioligand (2009) (60)
PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo (1994) (59)
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl (2016) (59)
Synthesis of suicide inhibitors of monoamine oxidase: Carbon‐11 labeled clorgyline, L‐deprenyl and D‐deprenyl (1988) (59)
In-target produced [11C]methane: Increased specific radioactivity. (2009) (59)
Positron Emission Tomographic Measurements of Cerebral Glucose Utilization Using [1-11C]D-Glucose (1990) (59)
Changes in dopamine D2-receptor binding are associated to symptom reduction after psychotherapy in social anxiety disorder (2012) (58)
[18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine transporter (1997) (58)
Reduced 5-HT1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder (2014) (58)
Application of cross-species PET imaging to assess neurotransmitter release in brain (2015) (58)
Fenfluramine‐induced serotonin release decreases [11C]AZ10419369 binding to 5‐HT1B‐receptors in the primate brain (2010) (58)
High 5HT2A receptor occupancy in M100907-treated schizophrenic patients (2000) (58)
Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking (2016) (58)
[carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo (1998) (57)
Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain (2014) (57)
Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. (1997) (56)
Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity (2003) (56)
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635 (2006) (55)
PET analysis of [11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls (1993) (55)
Metabolism of the PET ligand [11C]SCH 23390. Identification of two radiolabelled metabolites with HPLC (1994) (53)
[11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies (2005) (53)
Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I (2007) (53)
Improved specific radioactivity of the PET radioligand [11C]FLB 457 by use of the GE medical systems PETtrace MeI microlab (2000) (52)
Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. (2009) (52)
In vitro and in vivo characterisation of nor-β-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain (1997) (52)
Measurement of serotonin transporter binding with PET and [11C]MADAM: A test–retest reproducibility study (2006) (51)
Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. (2012) (51)
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET (2011) (50)
Dopamine D1 receptor number — a sensitive PET marker for early brain degeneration in Huntington's disease (2005) (50)
Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability (2010) (49)
Maps of receptor binding parameters in the human brain — a kinetic analysis of PET measurements (2004) (49)
Radioligands for the study of brain 5-HT(1A) receptors in vivo--development of some new analogues of way. (2000) (49)
Quantitative Analysis of Norepinephrine Transporter in the Human Brain Using PET with (S,S)-18F-FMeNER-D2 (2008) (48)
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. (2007) (48)
Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography (1999) (48)
Synthesis of a [6-pyridinyl-18F]-labelled fluoro derivative of WAY-100635 as a candidate radioligand for brain 5-HT1A receptor imaging with PET. (2003) (47)
High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET (2005) (47)
Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents (2008) (47)
In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects (2016) (47)
Carbon-11 labelling of eticlopride in two different positions--a selective high-affinity ligand for the study of dopamine D-2 receptors using PET. (1990) (47)
Comparison of [11C]methyl triflate and [11C]methyl iodide in the synthesis of PET radioligands such as [11C]β-CIT and [11C]β-CFT (1995) (46)
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635 (2006) (46)
Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study (2019) (46)
Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole (2002) (46)
Radioligands for the study of brain 5-HT1A receptors in vivo. (2001) (46)
Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. (1998) (45)
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 — Estimating occupancy in the absence of a reference region (2013) (44)
PET imaging of [11C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding (2018) (44)
The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. (2002) (44)
Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine (2002) (44)
Regional increases in [11 C]flumazenil binding after epilepsy surgery (1998) (44)
PET-MR and SPECT-MR multimodality probes: Development and challenges (2018) (44)
N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier (2010) (44)
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2 (2019) (43)
Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study (2003) (43)
PET radioligands for dopamine receptors and re-uptake sites: chemistry and biochemistry. (1992) (43)
Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging (1998) (43)
Implications of brain imaging for the management of schizophrenia (1998) (42)
A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain (2007) (42)
Error Analysis for Quantification of [11C]FLB 457 Binding to Extrastriatal D2 Dopamine Receptors in the Human Brain (2001) (42)
Dopamine D1-receptor binding in the living human brain. (1986) (42)
[125I]β-CIT-FE and [125I]β-CIT-FP are superior to [125I]β-CIT for dopamine transporter visualization: Autoradiographic evaluation in the human brain (1997) (42)
A facile and regioselective synthesis of rimonabant through an enamine-directed 1,3-dipolar cycloaddition (2008) (42)
Dopamine D2/3 receptor occupancy of apomorphine in the nonhuman primate brain—A comparative PET study with [11C]raclopride and [11C]MNPA (2009) (41)
Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography (2011) (41)
A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. (1999) (41)
Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients (1996) (40)
Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β‐CIT‐FE, by the use of [11C]methyl triflate (1998) (40)
Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography. (2010) (40)
Regional cerebral oxidative and total glucose consumption during rest and activation studied with positron emission tomography. (1994) (40)
Pharmacological characterization of 2‐methoxy‐N‐propylnorapomorphine's interactions with D2 and D3 dopamine receptors (2009) (40)
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder (2012) (40)
A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel‐Based Morphometry (2010) (39)
Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). (2013) (39)
Modulation of striatal dopamine D1 binding by cognitive processing (2009) (39)
Synthesis and biological evaluation of technetium(III) mixed-ligand complexes with high affinity for the cerebral 5-HT(1A) receptor and the alpha1-adrenergic receptor. (2002) (38)
Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. (2006) (38)
Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development. (2000) (38)
Quantification of serotonin transporter availability with [11C]MADAM — A comparison between the ECAT HRRT and HR systems (2010) (38)
AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. (2013) (38)
Guidelines for the content and format of PET brain data in publications and archives: A consensus paper (2020) (37)
[11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. (1993) (37)
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study (2019) (37)
Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D-1 receptor ligand, and preliminary PET investigations. (1991) (37)
Synthesis and structure-activity relationships (SARs) of 1,5-diarylpyrazole cannabinoid type-1 (CB(1)) receptor ligands for potential use in molecular imaging. (2006) (36)
Confirmation of Fenfluramine Effect on 5-HT1B Receptor Binding of [11C]AZ10419369 using an Equilibrium Approach (2012) (35)
Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter (2006) (35)
Autoradiography with saturation experiments of 11C-Ro 15–1788 binding to human brain sections (1991) (35)
Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain (2018) (35)
Quantification of serotonin transporter availability with [11C]MADAM — A comparison between the ECAT HRRT and HR systems (2010) (35)
Cerebral uptake of 11C—Ro 15—1788 and its acid metabolite 11C—Ro 15—3890; PET study in healthy volunteers (1989) (35)
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. (2008) (34)
The transport of tyrosine into the human brain as determined with L-[1-11C]tyrosine and PET. (1991) (34)
GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models (2018) (34)
Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study (2006) (34)
Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation. (2002) (34)
Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates (2015) (34)
An mGlu4‐Positive Allosteric Modulator Alleviates Parkinsonism in Primates (2018) (33)
Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2 (2010) (33)
Synthesis and evaluation of N-(5-fluoro-2-phenoxyphenyl)-N-(2-[(18)F]fluoromethoxy-d(2)-5-methoxybenzyl)acetamide: a deuterium-substituted radioligand for peripheral benzodiazepine receptor. (2005) (33)
Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol-PET tracers for the adrenergic nervous system of the heart. (2001) (33)
Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET (2011) (33)
Late‐Stage Isotopic Carbon Labeling of Pharmaceutically Relevant Cyclic Ureas Directly from CO2 (2018) (33)
Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. (2000) (33)
Brain Uptake and Plasma Metabolism of [11C]Vinpocetine: A Preliminary PET Study in a Cynomolgus Monkey (1999) (33)
Highly efficient synthesis of [11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET (2000) (33)
Arrestin3 mediates D2 dopamine receptor internalization (2009) (33)
Neuroimaging and Physiological Evidence for Involvement of Glutamatergic Transmission in Regulation of the Striatal Dopaminergic System (2009) (32)
Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects (2011) (32)
[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. (2003) (32)
Quality Assurance and Quality Control of Short-Lived Radiopharmaceuticals for PET (1993) (32)
Effects of estrogen and testosterone treatment on serotonin transporter binding in the brain of surgically postmenopausal women – a PET study (2015) (31)
Radiosynthesis of the candidate β‐amyloid radioligand [11C]AZD2184: Positron emission tomography examination and metabolite analysis in cynomolgus monkeys (2010) (31)
Synthesis, biological and autoradiographic evaluation of a novel Tc-99m radioligand derived from WAY 100635 with high affinity for the 5-HT(1A) receptor and the alpha1-adrenergic receptor. (2002) (31)
The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. (2016) (31)
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease (2010) (31)
Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter — Application to juvenile myoclonic epilepsy (2012) (31)
Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA (2008) (31)
Mapping of Central D2Dopamine Receptors in Man Using [11C]Raclopride: PET with Anatomic Standardization Technique (1999) (31)
Dopamine D2 receptors in the rat, monkey and the post-mortem human hippocampus. An autoradiographic study using the novel D2-selective ligand 125I-NCQ 298 (1991) (31)
Radiosynthesis of [18F]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET (2006) (30)
Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2 (2008) (30)
PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. (1996) (30)
5-HT1A receptor and 5-HTT binding during the menstrual cycle in healthy women examined with [11C] WAY100635 and [11C] MADAM PET (2009) (30)
Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain (2019) (30)
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain (2003) (30)
Distribution of messenger RNAs for D1 dopamine receptors and DARPP-32 in striatum and cerebral cortex of the cynomolgus monkey: Relationship to D1 dopamine receptors (1995) (30)
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [ 11 C ]RGH-1756 in the monkey brain (2004) (30)
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer (2020) (30)
Preparation of [76Br]FLB 457 and [76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET. (1996) (29)
Synthesis of some 11C-labelled alkaloids (1982) (29)
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD) (2014) (29)
In Vivo Visualization of β-Cells by Targeting of GPR44 (2017) (29)
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study (2011) (29)
Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). (2012) (29)
A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone (1995) (29)
Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A. (2015) (29)
Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. (2017) (29)
PET radioligands targeting the brain GABAA /benzodiazepine receptor complex. (2013) (28)
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease (2015) (28)
On-line synthesis of [11C]nitroalkanes. (1989) (28)
Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain (2014) (28)
In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors (2014) (28)
Decreased thalamic D 2 / D 3 receptor binding in drug-naive patients with schizophrenia : a PET study with [ 11 C ] FLB 457 (2003) (28)
Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. (2011) (28)
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR. (2013) (28)
Selectivity of 3H‐MADAM binding to 5‐hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects (2004) (28)
[125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer’s disease (2012) (28)
Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369 (2011) (28)
An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters (2012) (28)
New developments of dopaminergic imaging in Parkinson's disease. (2012) (28)
Precursor synthesis and radiolabelling of [11C]ADAM: a potential radioligand for the serotonin transporter exploration by PET (2001) (27)
An evaluation of a high-pressure (11)CO carbonylation apparatus. (2015) (27)
Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. (1999) (27)
Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study (1995) (27)
Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography (2010) (27)
[11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding (1992) (27)
Activation of glucocorticoid receptors increases 5-HT2A receptor levels (2009) (27)
Extrastriatal dopamine D2 receptor binding in Huntington's disease (2011) (27)
Search for correlations between serotonin 5-HT1A receptor expression and cognitive functions—a strategy in translational psychopharmacology (2006) (27)
A human [11C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor (2016) (27)
Kinetic Analysis and Quantification of the Dopamine Transporter in the Nonhuman Primate Brain with 11C-PE2I and 18F-FE-PE2I (2011) (27)
N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors. (2011) (26)
Quantitative analysis of 18F-FE-PE2I binding to the dopamine transporter in Parkinson’s disease (2015) (26)
A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression (2020) (26)
Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT (2012) (26)
Evaluation of Two Automated Methods for PET Region of Interest Analysis (2014) (26)
New halogenated [11C]WAY analogues, [11C]6FPWAY and [11C]6BPWAY--radiosynthesis and assessment as radioligands for the study of brain 5-HT1A receptors in living monkey. (2001) (26)
Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease (2014) (25)
D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects (1997) (25)
PET-Determination of Robalzotan (NAD-299) Induced 5-HT1A Receptor Occupancy in the Monkey Brain (2000) (25)
PET imaging of neuroreceptors in schizophrenia (1995) (25)
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain (2017) (25)
Radiolabeling of a high potency cannabinoid subtype‐1 receptor ligand, N‐(4‐fluoro‐benzyl)‐4‐(3‐(piperidin‐1‐yl)‐indole‐1‐sulfonyl)benzamide (PipISB), with carbon‐11 or fluorine‐18 (2008) (25)
Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[18F]FMeNER-D2 (2009) (25)
Arterial Input Function Derived from Pairwise Correlations Between PET-image Voxels (2013) (25)
Synthesis of unlabelled, 3H‐ and 125I‐labelled β‐CIT and its ϖ‐fluoroalkyl analogues β‐CIT‐FE and β‐CIT‐FP, including synthesis of precursors (1996) (25)
Guidelines to PET measurements of the target occupancy in the brain for drug development (2016) (25)
Effects of amphetamine on the human brain opioid system – a positron emission tomography study (2012) (24)
Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B). (2011) (24)
Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter. (1999) (24)
PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. (1999) (24)
Characterization of C‐11 or I‐123 Labelled β‐CIT‐FP and β‐CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC (1996) (24)
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study (2013) (24)
Direct plasma metabolite analysis of positron emission tomography radioligands by micellar liquid chromatography with radiometric detection. (2012) (24)
Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter (1995) (24)
Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2 (2007) (24)
Ligand metabolites in plasma during PET‐studies with the 11C‐labelled dopamine antagonists, raclopride, SCH 23390 and N‐methylspiroperidol (1992) (24)
Dopamine β‐hydroxylase‐deficient mice have normal densities of D2 dopamine receptors in the high‐affinity state based on in vivo PET imaging and in vitro radioligand binding (2010) (24)
Amyloid binding properties of curcumin analogues in Alzheimer’s disease postmortem brain tissue (2016) (24)
Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors. (2008) (23)
Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride (2013) (23)
Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men (1997) (23)
Human brain imaging post-mortem - whole hemisphere technologies (2001) (23)
Identification of PET radiometabolites by cytochrome P450, UHPLC/Q-ToF-MS and fast radio-LC: applied to the PET radioligands [11C]flumazenil, [18F]FE-PE2I, and [11C]PBR28 (2013) (23)
Positron Emission Tomography studies with [11C]PBR28 in the Healthy Rodent Brain: Validating SUV as an Outcome Measure of Neuroinflammation (2015) (23)
Extrastriatal dopamine D2-receptor availability in social anxiety disorder (2017) (23)
Sample preparation techniques for radiometabolite analysis of positron emission tomography radioligands; trends, progress, limitations and future prospects (2019) (23)
GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans (2016) (23)
In vivo evaluation in cynomolgus monkey brain and metabolism of [18F]fluorodeprenyl: A new MAO‐B pet radioligand (2012) (22)
Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. (2015) (22)
Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: A PET study (2014) (22)
Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Blood–Brain Barrier (2013) (22)
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients (2019) (22)
Preclinical Characterization of a Novel Class of 18F-Labeled PET Tracers for Amyloid-β (2012) (22)
A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. (2004) (22)
Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect (2017) (22)
A PET study of [11C]β-CIT-FE binding to the dopamine transporter in the monkey and human brain (2000) (22)
Carbon-11 pb-12: an attempt to visualize the dopamine d(4) receptor in the primate brain with positron emission tomography. (2000) (22)
Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. (1999) (22)
Selective synthesis of racemic 1-11C-labelled norepinephrine, octopamine, norphenylephrine and phenylethanolamine using [11C]nitromethane. (1994) (21)
Quantitative PET Analysis of the Dopamine D2 Receptor Agonist Radioligand 11C-(R)-2-CH3O-N-n-Propylnorapomorphine in the Human Brain (2009) (21)
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390 (2017) (21)
Synthesis of racemic [3-11C]phenylalanine and [3-11C]DOPA (1984) (21)
Synthesis of [11C]-labelled Aldehydes. (1984) (21)
Studies on the binding of [3H]flumazenil and [3H]sarmazenil in post‐mortem human brain (1992) (21)
18F-MCL-524, an 18F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study (2014) (21)
[11C]LBT‐999: A suitable radioligand for investigation of extra‐striatal dopamine transporter with PET (2007) (21)
In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects (2017) (21)
Dopamine D2 receptor quantification in extrastriatal brain regions using [123I]epidepride with bolus/infusion (2000) (21)
Utilization of radioligands in schizophrenia research. (1995) (21)
European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) receptor ligands. (2002) (20)
PET examination of [(11)C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter. (2002) (20)
Palladium mediated ¹¹C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [¹¹C]AZD9272. (2013) (20)
PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression (2020) (20)
Specific in vitro binding of (S,S)‐[3H]MeNER to norepinephrine transporters (2005) (20)
D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. (1998) (20)
Development of a Small D-Enantiomeric Alzheimer’s Amyloid-β Binding Peptide Ligand for Future In Vivo Imaging Applications (2012) (20)
PET Radiopharmaceutical Metabolism — Plasma Metabolite Analysis (1993) (20)
Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPET (2003) (20)
Brain exposure of the ATM inhibitor AZD1390 in humans - a positron emission tomography (PET) study. (2020) (20)
Evidence of fatigue, disordered sleep and peripheral inflammation, but not increased brain TSPO expression, in seasonal allergy: A [11C]PBR28 PET study (2018) (20)
Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer’s disease patients (2013) (20)
5‐HT1B receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients (2015) (20)
Approaches to quantify radioligands that wash out slowly from target organs (2010) (20)
PET STUDIES OF DOPAMINE RECEPTORS IN RELATION TO ANTIPSYCHOTIC DRUG TREATMENT (1992) (19)
11C-carbonylation reactions using gas–liquid segmented microfluidics (2015) (19)
Imaging Mutant Huntingtin Aggregates: Development of a Potential PET ligand. (2020) (19)
Different brain radioactivity curves in a PET study with [11C]beta-CIT labelled in two different positions. (1999) (19)
PET studies of D2‐receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans (2010) (19)
The pyridinyl-6 position of WAY-100635 as a site for radiofluorination--effect on 5-HT1A receptor radioligand behavior in vivo. (2004) (19)
Binding of [3H]SCH 39166 to human post mortem brain tissue. (1993) (19)
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using ( S , S )-[18F]FMeNER-D2 (2006) (19)
Determination of plasma protein binding of positron emission tomography radioligands by high-performance frontal analysis. (2014) (19)
Evaluation of a novel PDE10A PET radioligand, [11C]T‐773, in nonhuman primates: Brain and whole body PET and brain autoradiography (2015) (19)
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline (2016) (19)
High specific radioactivity (1R,2S)-4-[(18)F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. (2000) (19)
Short and efficient syntheses of analogues of WAY-100635: new and potent 5-HT1A receptor antagonists. (2001) (19)
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients (2016) (19)
Asymmetric synthesis of L-[3-11C] phenylalanine using chiral hydrogenation catalysts (1984) (19)
Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET. (2007) (18)
Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man (1995) (18)
N-oxide analogs of WAY-100635: new high affinity 5-HT(1A) receptor antagonists. (2005) (18)
11C‐Methionine Kinetics in Pregnant Rhesus Monkeys Studied by Positron Emission Tomography: A New Approach to Feto‐Maternal Metabolism (1984) (18)
Fluorine-18 labeling of three novel D-peptides by conjugation with N-succinimidyl-4-[18F]fluorobenzoate and preliminary examination by postmortem whole-hemisphere human brain autoradiography. (2012) (18)
Serotonin transporter availability in adults with autism—a positron emission tomography study (2020) (18)
Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder (2016) (18)
Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study (2007) (18)
Amphetamine Decreases α2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain (2015) (18)
A fully automated one-pot synthesis of [carbonyl-11C]WAY-100635 for clinical PET applications. (2009) (18)
Synthesis, radiolabeling and preliminary biological evaluation of radiolabeled 5-methyl-6-nitroquipazine, a potential radioligand for the serotonin transporter. (2002) (17)
PET Studies of Binding Competition Between Endogenous Dopamine and the D 1 (1999) (17)
A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration (2004) (17)
N-(5-Fluoro-2-phenoxyphenyl)-N-(2-[(131)I]iodo-5-me thoxybenzyl)acetamide: a potent iodinated radioligand for the peripheral-type benzodiazepine receptor in brain. (2007) (17)
The Bücherer-Strecker synthesis of d- and l-(1-11C)tyrosine and the in vivo study of l-(1-11C)tyrosine in human brain using positron emission tomography (2004) (17)
Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity. (2013) (17)
Preparation of [18F]β-CFT-FP and [11C]β-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET) (2000) (17)
Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex (2017) (17)
A direct comparison of the brain uptake and plasma clearance of N-[11C]methylspiroperidol and [18F]N-methylspiroperidol in baboon using PET. (1986) (17)
NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo (2011) (17)
Improved Yields for the Palladium-Mediated 11C-Carbonylation Reaction Using Microwave Technology (2014) (17)
Synthesis and initial evaluation of [11C](R)-RWAY in monkey—a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET (2007) (17)
Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram (2005) (17)
11C-labelling of dimethylphenethylamine in two different positions and biodistribution studies. (1989) (17)
Development of radioligands for imaging of brain norepinephrine transporters in vivo with positron emission tomography. (2007) (17)
A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies (2019) (17)
Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756 (2005) (17)
Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand. (1991) (17)
Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography (1997) (16)
Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[&bgr;-11C]DOPA and [18F]FE-PE2I in humans (2014) (16)
Synthesis of [3-11C]phenylpyruvic acid and its use in an enzymatic transamination to [3-11C]phenylalanine (1986) (16)
Synthesis of [1-11C]D-glucose and [1-11C]D-mannose from on-line produced [11C]nitromethane. (1991) (16)
Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography (2019) (16)
The development of a GPR44 targeting radioligand [11C]AZ12204657 for in vivo assessment of beta cell mass (2018) (16)
Alkyl Iodides and [11C]CO in Nickel‐Mediated Cross‐Coupling Reactions: Successful Use of Alkyl Electrophiles containing a β Hydrogen Atom in Metal‐Mediated [11C]Carbonylation (2016) (16)
Imaging of the Striatal and Extrastriatal Dopamine Transporter with 18F-LBT-999: Quantification, Biodistribution, and Radiation Dosimetry in Nonhuman Primates (2011) (16)
Synthesis of ([(11)C]carbonyl)raclopride and a comparison with ([(11)C]methyl)raclopride in a monkey PET study. (2015) (16)
Comparative double-tracer whole-body autoradiography: uptake of 11C-, 18F- and 3H-labeled compounds in rat tumors. (1988) (16)
Central D2 receptor occupancy and effects of zuclopenthlxol acetate in humans (1995) (16)
Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates (2005) (16)
Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies. (2012) (16)
Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors. (1990) (15)
Performance Evaluation of a High-Resolution Nonhuman Primate PET/CT System (2019) (15)
Evaluation of [11C]PipISB and [18F]PipISB in monkey as candidate radioligands for imaging brain cannabinoid type‐1 receptors in vivo (2009) (15)
Identification and development of an irreversible monoacylglycerol lipase (MAGL) positron emission tomography (PET) radioligand with high specificity. (2019) (15)
Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine. (2011) (15)
Validation of [11C]ORM‐13070 as a PET tracer for alpha2c‐adrenoceptors in the human brain (2015) (15)
Radiofluorination and reductive amination using a microfluidic device (2012) (15)
[18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. (1997) (15)
11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET (2005) (15)
Cerebral uptake of [ethyl-11C]vinpocetine and 1-[11C]ethanol in cynomolgous monkeys: a comparative preclinical PET study. (2002) (15)
Age-related diurnal effect on D2 receptor binding: a preliminary PET study. (2008) (15)
Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11C]cariprazine: An in vivo positron emission tomography study in nonhuman primates (2013) (15)
Test-retest reproducibility of [11C]-l-deprenyl-D2 binding to MAO-B in the human brain (2017) (15)
Brain PET measurement of PDE10A occupancy by TAK‐063, a new PDE10A inhibitor, using [11C]T‐773 in nonhuman primates (2016) (15)
Synthesis and PET evaluation of (R)‐[S‐methyl‐11C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters (2006) (15)
Preparation of 4-[11C]Methylmetaraminol a Potential PET Tracer for Assessment of Myocardial Sympathetic Innervation (2001) (15)
Positron Emission Tomography Studies on Dopamine Receptors in Schizophrenia (1995) (15)
New alpha(1)-adrenoceptor antagonists derived from the antipsychotic sertindole - carbon-11 labelling and pet examination of brain uptake in the cynomolgus monkey. (2004) (15)
Peripheral benzodiazepine binding sites in human gliomas evaluated with positron emission tomography. (1986) (14)
Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET) (2004) (14)
Synthesis of racemic [α-11C]amphetamine and [α-11C]phenethylamine from [11C]nitroalkanes (1992) (14)
Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments. (2007) (14)
Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study (2017) (14)
Development of [11C]/[3H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand. (2017) (14)
P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects (2008) (14)
Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER (2009) (13)
[11C]beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. (1996) (13)
Preparation of 4-[11C]methylmetaraminol, a potential PET tracer for assessment of myocardial sympathetic innervation: PREPARATION OF 4-[11C] METHYLMETARAMINOL (2003) (13)
Z-IQNP: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer’s disease (2000) (13)
Synthesis and preclinical evaluation of [18F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B. (2019) (13)
[11C]metaraminol, a false neurotransmitter: preparation, metabolite studies and positron emission tomography examination in monkey. (1996) (13)
"Mixed" anionic and non-ionic micellar liquid chromatography for high-speed radiometabolite analysis of positron emission tomography radioligands. (2013) (13)
Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. (2013) (13)
Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man (1995) (13)
Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1 and M2 muscarinic acetylcholine receptors in Alzheimer’s disease (1999) (13)
Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain (2018) (13)
Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET (1991) (13)
Localization of monoamine oxidase B in human brain by autoradiographical use of11C-labelled L-deprenyl (2005) (13)
Saturation of striatal D(2) dopamine receptors by clozapine. (2002) (12)
Investigation of the Metabolites of (S,S)-[11C]MeNER in Humans, Monkeys and Rats (2008) (12)
A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers (2013) (12)
11C- and 76Br-labelled NNC 22-0010, selective dopamine D1 receptor radioligands for PET. (1996) (12)
Enhanced Sampling Simulations of Ligand Unbinding Kinetics Controlled by Protein Conformational Changes (2019) (12)
Development of 123I-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding. (1996) (12)
Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain (2016) (12)
Comparison of [11C]methyl triflate and [11C]methyl iodide in the synthesis of PET radioligands such as [11C]beta-CIT and [11C]beta-CFT. (1995) (12)
Serotonin transporter availability increases in patients recovering from a depressive episode (2021) (12)
SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP (2001) (12)
Quantitative analysis of ( 11 C)AZ10419369 binding to 5-HT 1B receptors in human brain (2011) (12)
Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain. (2018) (12)
Preparation of [1-11C]dopamine, [1-11C]p-tyramine and [1-11C]m-tyramine. Autoradiography and PET examination of [1-11C]dopamine in primates. (1993) (12)
Rapid metabolite analysis of positron emission tomography radioligands by direct plasma injection combining micellar cleanup with high submicellar liquid chromatography with radiometric detection. (2012) (12)
Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET) (1997) (11)
505 D1-Dopamine receptors in schizophrenia examined by pet (1997) (11)
Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain. (2020) (11)
The labelling of 2‐oxoquazepam with electrophilic 18F (1991) (11)
Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA, a dopamine agonist radioligand (2008) (11)
The dopamine D1 receptor agonist (S)‐[11C]N‐methyl‐NNC 01‐0259 is not sensitive to changes in dopamine concentration—a positron emission tomography examination in the monkey brain (2013) (11)
Gpp(NH)p stimulates [3H]raclopride binding to homogenates from human putamen and accumbens (1992) (11)
PET technology for drug development in psychiatry (2020) (11)
Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. (2009) (11)
The metabotropic glutamate receptor 5 radioligand [11C]AZD9272 identifies unique binding sites in primate brain (2018) (11)
A two-step one-pot radiosynthesis of the potent dopamine D2/D3 agonist PET radioligand [11C]MNPA (2009) (11)
Molecular Imaging of PDE10A Knockout Mice with a Novel PET Radiotracer: [11C]T-773 (2015) (11)
Efficient DBU accelerated synthesis of 18F-labelled trifluoroacetamides. (2016) (11)
Development of a series of novel carbon-11 labeled PDE10A inhibitors. (2015) (11)
Rapid and Efficient Synthesis of 11 C-Labeled Benzimidazolones Using [11 C]Carbon Dioxide (2019) (11)
ドーパミンD‐2受容体の研究のための選択的リガンドである,(S)‐3‐ヨウ化‐5,6‐ジメトキシ‐N‐[(1‐エチル‐2‐ピロリジニル)メチル]サリチルアミド(NCQ298)と,その〔123I〕,〔125I〕ラベル化物の合成 (1990) (10)
PET-determination of benzodiazepine receptor binding in studies on alcoholism. (1994) (10)
P.1.c.022 PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates (2007) (10)
Synthesis of racemic [2-11C]phenylglycine (1985) (10)
Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator (2019) (10)
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates (2016) (10)
Radiochemical labelling of the dopamine D3 receptor ligand RGH‐1756 (2000) (10)
Short communication Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-( 18 F)FMeNER-D 2 (2005) (10)
Synthesis, Radiolabeling, and In Vivo Pharmacokinetic Evaluation of the Amyloid Beta Radioligand [11C]AZD4694 in Nonhuman Primates (2014) (10)
Synthesis of [ethyl‐18F]fluororaclopride for the in vivo study of dopamine D2 receptors using PET (1989) (10)
Development of two fluorine-18 labeled PET radioligands targeting PDE10A and in vivo PET evaluation in nonhuman primates. (2018) (10)
Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects (2018) (10)
PET-examination and metabolite evaluation in monkey of [(11)C]NAD-299, a radioligand for visualisation of the 5-HT(1A) receptor. (2002) (9)
A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[11C]Rolipram (2018) (9)
[11C]SCH23390 binding to the D1-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis (2018) (9)
Mesial temporal lobe epilepsy is associated with limbic reductions in serotonin 5HT1A receptor binding (2001) (9)
Chapter 24 Discovery of Novel Positron Emission Tomography Tracers (2009) (9)
Improved radiometabolite analysis procedure for positron emission tomography (PET) radioligands using a monolithic column coupled with direct injection micellar/high submicellar liquid chromatography. (2013) (9)
Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain (2015) (9)
Radiosynthesis and evaluation of new α1-adrenoceptor antagonists as PET radioligands for brain imaging. (2013) (9)
Preparation of 4- and 6-[76Br] bromometaraminol, two potential radiotracers for the study of the myocardial norepinephrine neuronal reuptake system with pet (1997) (9)
Imaging of dopamine receptors using PET and SPECT (1992) (9)
The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans (2020) (9)
Synthesis of 2β‐carbomethoxy‐3β‐(4‐[76Br]bromophenyl)tropane ([76Br]β‐CBT), a pet tracer for in vivo imaging of the dopamine uptake sites (1995) (9)
Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates (2019) (9)
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [11C]MADAM PET study (2015) (9)
Characterization of [11C]PXT012253 as a PET Radioligand for mGlu4 Allosteric Modulators in Nonhuman Primates (2018) (9)
[125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. (1997) (9)
[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins. (2021) (8)
Distribution and binding of 18F-labeled and 125I-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: A whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer’s disease patients (2012) (8)
Abstract CT013: Osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with11C-labelled osimertinib (2018) (8)
Reduction of [11 C]CO2 to [11 C]CO using solid supported zinc. (2017) (8)
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data (2016) (8)
Brain Dopamine Receptors in Schizophrenia: PET Problems-Reply (1988) (8)
Effects of cocaine on [11C]norepinephrine and [11C]β-CIT uptake in the primate peripheral organs measured by PET (1996) (8)
Synthesis of a delta opioid agonist in [2H6], [2H4], [11C], and [14C] labeled forms (2011) (8)
Revisiting the Logan plot to account for non-negligible blood volume in brain tissue (2017) (8)
The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method (1995) (8)
Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241) (1996) (8)
Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain (2016) (8)
Development of radioligands for the dopamine transporter (1996) (8)
Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies (2019) (8)
[11C]AZ10419096 - a full antagonist PET radioligand for imaging brain 5-HT1B receptors. (2017) (8)
[11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors. (2008) (8)
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort (2020) (8)
Remote-controlled production of [1-11C]-d-glucose and evaluation of the effect of labelling position on loss of [11C]CO2 (1992) (8)
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomography. (1994) (7)
Autoradiographic evaluation of [11C]vinpocetine binding in the human postmortem brain. (2002) (7)
Imaging and Quantitation of Cannabinoid CB 1 Receptors in Human and Monkey Brains (2010) (7)
Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease (2020) (7)
Direct and Efficient (Carbonyl)cobalt‐Mediated Aryl Acetylation Using [11C]Methyl Iodide (2016) (7)
Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice (2020) (7)
Simultaneous determination of protein-free and total positron emission tomography radioligand concentrations in plasma using high-performance frontal analysis followed by mixed micellar liquid chromatography: application to [11C]PBR28 in human plasma. (2013) (7)
Short Communication Fenfluramine-Induced Serotonin Release Decreases ( 11 C)AZ10419369 Binding to 5-HT 1B -Receptors in the Primate Brain (2010) (7)
Dealing with PET radiometabolites (2020) (7)
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain (2019) (7)
Two C-Methyl Derivatives of [11C]WAY-100635 – Effects of an Amido α-Methyl Group on Metabolism and Brain 5-HT1A Receptor Radioligand Behavior in Monkey* (2005) (7)
Joint explorative analysis of neuroreceptor subsystems in the human brain: application to receptor–transporter correlation using PET data (2004) (7)
Development of new brain imaging agents based upon nocaine-modafinil hybrid monoamine transporter inhibitors. (2006) (7)
Synthesis of [p-methyl-11C]RTI-32: A new tool for the in vivo evaluation of the metabolism of phenyltropane dopamine reuptake compounds (1999) (7)
Synthesis of [11C]sodium thiocyanate for in vivo studies of anion kinetics using positron emission tomography (PET). (1989) (7)
“In‐loop” carbonylation—A simplified method for carbon‐11 labelling of drugs and radioligands (2020) (7)
The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson’s Disease (2019) (7)
Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study (2017) (7)
Human Brain Imaging of Dopamine Transporters (2014) (7)
Immunohistoblot analysis on whole human hemispheres from normal and Alzheimer diseased brains (2008) (6)
Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo (2020) (6)
Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography (2000) (6)
Positron emission tomographic imaging in drug discovery. (2021) (6)
Radioligands for Dopamine Receptor PET Studies: Benzamides and Ligands for Dopamine D-1 Receptors (1991) (6)
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart (1994) (6)
Synthesis of 3H- and 14C-labeled tracers for studies of functional monoamine oxidase activity (1988) (6)
Development of a 18F-labeled PET radioligand for imaging 5-HT1B receptors: [18F]AZ10419096. (2019) (6)
[11C]NNC 22-0215, a metabolically stable dopamine D1 radioligand for PET. (1998) (6)
Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the α7 nicotinic acetylcholine receptor. (2016) (6)
Radiosynthesis of [11C]ximelagatran via palladium catalyzed [11C]cyanation (2008) (6)
Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis (2021) (6)
Synthesis and biological evaluation of [¹¹C]AZ12504948; a novel tracer for imaging of glucokinase in pancreas and liver. (2015) (6)
PET for drug development. (2004) (6)
In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659 (2019) (6)
Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT1B receptors. (2019) (6)
Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains (2017) (6)
Synthesis of nor-β-CIT, β-CIT and trimethylstannyl-β-CT (1995) (5)
Dopamine D2/D3 receptor occupancy of apomorphine evaluated with the agonist radioligand [11C]MNPA and the antagonist radioligand [11C]Raclopride. A PET evaluation in the non-human primate brain (2006) (5)
Autoradiographical evaluation of novel high‐affinity Tc‐99m ligands for the serotonin 5‐HT1A receptor (2001) (5)
Alternative labelling of the cocaine analogue isomers α-CIT and β-CIT by direct iodination with no-carrier-added Na125I (1994) (5)
ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [11C]AZ10419369: a comparative PET study in mouse, rat, and guinea pig (2014) (5)
[11C]raclopride positron emission tomography study of dopamine‐D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects (2020) (5)
Synthesis and radiolabelling of 2β‐carbomethoxy‐3β‐(3′‐iodo‐4′‐isopropylphenyl) nortropane as a radioligand for the exploration of the serotonin transporter by SPET (1999) (5)
PET analysis of alcohol interaction with the brain disposition of [11C]flumazenil (2005) (5)
Synthesis and in vivo evaluation of a new PET radioligand for imaging the cannabinoid type-1 (CB1) receptors (2006) (5)
New developments of dopaminergic imaging in Parkinson's disease. (2012) (5)
AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β-amyloid deposits (2009) (5)
Toxicity, mutagenicity, and behavioral effects of beta-CIT, a ligand for dopamine transporter exploration by SPECT. (1998) (5)
76Br-β-CBT, a PET tracer for investigating dopamine neuronal uptake (1995) (5)
β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [11C]AZD2184 (2015) (5)
Synthesis of [18F]NNC 12-0817 and [18F]NNC 12-0818; two potential radioligands for the dopamine transporter. (1995) (5)
Evaluation of an inverse agonist with high affinity for the CB1 receptor, [11C]MePPEP, in rodents and humans (2008) (5)
Graphic plot analysis for estimating binding potential of translocator protein (TSPO) in positron emission tomography studies with [18F]FEDAA1106 (2013) (5)
Radiolabeling of two 11C-labeled formylating agents and their application in the preparation of [11C]benzimidazole (2012) (5)
D of 5-HT receptors in the postmortem human brain—an (2003) (5)
Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects (2020) (5)
NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors (2005) (5)
Evaluation and metabolite studies of 125I- and 123I-labelled E-(R,R)-IQNP: potential radioligands for visualization of M1 muscarinic acetylcholine receptors in brain. (1998) (5)
Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography (2018) (5)
Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors. (1997) (5)
Characterization of the binding mode of the PET tracer [18F]ASEM to a chimera structure of the α7 nicotinic acetylcholine receptor (2017) (4)
A fast and convenient method for robotic preparation of [11C]flumazenil avoiding HPLC purification (2000) (4)
Synthesis of racemic, R- and S-[1-11C]-β-hydroxybutyric acid (1991) (4)
[Cerebral uptake and regional distribution of [11C]-vinpocetin after intravenous administration to healthy men: a PET study]. (2002) (4)
In vitro evidence for competitive tspo binding of the imaging biomarker candidates vinpocetine and two iodinated daa1106 analogues in post mortem autoradiography experiments on whole hemisphere human brain slices (2009) (4)
Evaluation of [11C]ORM-13070 as a PET tracer for α2C-adrenoceptors in the human brain (2014) (4)
Development of a Novel Carbon-11 Labeled PET Radioligand for Melanin- Concentrating Hormone Receptor 1. (2017) (4)
Implementation of iMiDEV™, a new fully automated microfluidic platform for radiopharmaceutical production. (2021) (4)
Dr. Talvik and Colleagues Reply (2002) (4)
PET-Determination of Central D1- and D2-Dopamine Receptor Occupancy in Neuroleptic Treated Schizophrenics (1987) (4)
New approach in radiometabolite analysis of positron emission tomography (PET) radioligands; lead-shielded microextraction by packed sorbent as a tool for in vivo radiometabolite analysis of [11C]SMW139 in rat plasma. (2020) (4)
No correlation between serotonin and its metabolite 5‐HIAA in the cerebrospinal fluid and [11C]AZ10419369 binding measured with PET in healthy volunteers (2014) (4)
Synthesis of the benzodiazepine‐1 antagonist [18F]‐2‐oxoquazepam (1989) (4)
Synthesis of [11C]sodium thiocyanate and [isopropyl-11C]nimodipine for the in vivo study of ion channels using PET (1989) (4)
Dopamine Receptor Occupancy and Plasma Haloperidol Levels-Reply (1989) (4)
A simplified radiometabolite analysis procedure for PET radioligands using a solid phase extraction with micellar medium. (2013) (4)
Kinetic analysis and quantification of the dopamine transporter in the non-human primate brain with [11C]PE2I and [18F]FE-PE2I (2010) (4)
Pilot study on receptor binding and serotonin sensitivity of [11C]CIMBI-36 in monkey brain (2011) (4)
Development of 11C-Labeled ASEM Analogues for the Detection of Neuronal Nicotinic Acetylcholine Receptors (α7-nAChR) (2022) (4)
Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. (1995) (4)
Rapid and sensitive measurement of PET radioligands in plasma by fast liquid chromatography/radiometric detection. (2012) (4)
An In Vivo Study of a Rat Fluid-Percussion-Induced Traumatic Brain Injury Model with [11C]PBR28 and [18F]flumazenil PET Imaging (2021) (4)
Synthesis of [isopropyl-11C]nimodipine for in vivo studies of dihydropyridine binding in man using positron emission tomography. (1991) (4)
Dose-dependent binding of AZD3783 to brain 5-HT 1B receptors in non-human primates and human subjects: a positron emission tomography study (2011) (4)
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676 (2016) (4)
PET Imaging of VMAT2 with the Novel Radioligand [18F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [11C]DTBZ and [18F]FE-DTBZ (2021) (4)
Preparation of a potential positron emission tomographic radioligand for the dopamine transporter (1994) (3)
Potential for imaging the high-affinity state of the 5-HT1B receptor: a comparison of three PET radioligands with differing intrinsic activity (2019) (3)
Synthesis of nor-beta-CIT, beta-CIT and trimethylstannyl-beta-CT. (1995) (3)
[11C]MADAM Used as a Model for Understanding the Radiometabolism of Diphenyl Sulfide Radioligands for Positron Emission Tomography (PET) (2015) (3)
In-target produced [11C]methane meets the demands of increased specific radioactivity for neuroreceptor PET radioligands (2006) (3)
Scatchard Analysis of the D2 Receptor Agonist [C-11]MNPA in the Monkey Brain Using PET (2005) (3)
Positron emission tomography studies on dopamine receptors in Schizophrenia. Discussion (1995) (3)
Brain Tumor Imaging: European Association of Nuclear Medicine Procedure Guidelines (2011) (3)
Synthesis of 11C-labeled prostaglandins and positron emission tomography studies using the rhesus monkey. (1987) (3)
Escitalopram - the most selective SSRI; in vitro data and in vivo binding studies using the new selective SERT ligand 3H-MADAM (2002) (3)
PET probes for imaging pancreatic islet cells (2017) (3)
COMT inhibition prevents the formation of lipophilic radiometabolites of catechols, — An example with (S)-[11C]N-methyl-NNC 01-0259 (2008) (3)
RESEARCH ARTICLE Investigation of the Metabolites of (S,S)-( 11 C) MeNER in Humans, Monkeys and Rats (2009) (3)
New radioligands for pet-examination of central muscarinic receptors (1994) (3)
A new PET radioligand [11C]cyclopropyl-FLB 457 for imaging extrastriatal dopamine D2 receptors: Evaluation in monkey and comparison to [11C]FLB 457 and [11C]Fallypride (2006) (3)
PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511 (2020) (3)
Labeling of the dopamine transporter ligand β-CFT-FP with 18F or 11C (1999) (3)
Synthesis and evaluation of 2-chloro N-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl]3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET radioligand for glycine transporter 1 (2012) (3)
Autoradiography and saturation experiments with 11C-RO 15-1788 binding to human brain. (1991) (3)
PET evaluation of the partial dopamine D1 receptor agonist radioligands R- and S-[11C]N-Methyl-NNC 01-0259 (2006) (3)
Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [18F]FE-PE2I and PET. (2017) (3)
Synthesis of [1-11C]-beta-hydroxybutyric acid. (1991) (3)
Brain MAO-B inhibition in healthy elderly and people with Alzheimer's disease after oral administration of RO4602522 (2013) (3)
Autoradiographic studies of the labelling of 5-HT1A receptors in the post-mortem human brain using [11C]NAD-299 and [3H]NAD-299 (1998) (3)
Quantitative Analysis of 18F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain (2018) (3)
Sample preparation techniques for protein binding measurement in radiopharmaceutical approaches: A short review. (2020) (3)
Serotonin 5‐HT1A Receptor Imaging in the Human Brain with Positron‐Emission Tomography: Coordination and the Standardization and Dissemination of Methodology (2001) (3)
In vivo occupancy of the 5-HT1A receptor by a novel pan 5-HT1(A/B/D) receptor antagonist, GSK588045, using positron emission tomography (2015) (3)
A radiometabolite study of the serotonin transporter PET radioligand [(11)C]MADAM. (2014) (3)
Positron Emission Tomography (PET) Studies with Ligands for Cholinergic Receptors in the Human Brain (1995) (2)
Decreased defluorination using the novel beta- cell imaging agent ( 18 F)FE-DTBZ-d4 in pigs (2011) (2)
In vivo SPECT and ex vivo autoradiographic brain imaging of the novel selective CB1 receptor antagonist radioligand [125I]SD7015 in CB1 knock-out and wildtype mouse (2013) (2)
A PET study of [ 11 C ] β-CIT-FE binding to the dopamine transporter in the monkey and human brain (2000) (2)
Autoradiographic localisation of 5-HT receptors in the human brain (2002) (2)
[Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies]. (1999) (2)
In response to the letter “[11C]raclopride and extrastriatal binding to D2/3 receptors” (2019) (2)
Amphetamine decreases binding of the novel alpha2C-adrenoreceptor radioligand [11C]ORM-13070 in monkey brain (2010) (2)
Evaluation of a versatile process control system for a robot arm (1989) (2)
Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: 18F-AZD9272 (2020) (2)
E31 Positron Emission Tomography Imaging Of Phosphodiesterase 10 A Enzyme And Dopamine D2 Receptor In Huntington´s Disease Gene Expansion Carriers (2014) (2)
[11C]RO6899880, a novel agonist PET radioligand for the GABAA receptor (2013) (2)
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B (2020) (2)
Radiotoxicity of 11C-methionine measured by the accumulation of DNA strand breaks in mammalian cells (2004) (2)
Decreased D1-dopamine receptor binding in drug naive schizophrenic patients examined by pet (1995) (2)
Astrocytosis precedes amyloid deposition in Alzheimer's Tg2576 APPswe transgenic mice: A multi-tracer microPET imaging study (2013) (2)
Radiosynthesis and Evaluation in Monkey of Three 11C-Labeled 1,5-Diarylpyrazoles as High Potency Candidate PET Radioligands for Cannabinoid Subtype-1 Receptors in Brain (2008) (2)
Quantitative analyses of [11C]AZ10419369 binding to 5-HT1B receptors in the human brain (2008) (2)
[125I]6IPWAY — a candidate radioligand for the 5-HT1A receptor — radiolabeling and preliminary examination with human post mortem autoradiography (2001) (2)
Radioactive metabolites of the 5-HT1A receptor pet radioligand, [carbonyl-11C]way-100635, measured in human plasma samples (2001) (2)
LIGAND SELECTION FOR PET STUDIES OF D1 DOPAMINE RECEPTORS. RELATIONSHIP BETWEEN DISTRIBUTION OF BINDING SITES AND mRNA FOR DAARPP32 IN THE HUMAN BRAIN (1992) (2)
Signal transduction pathway activity compensates dopamine D2/D3 receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [3H]raclopride and [35S]GTPγS (2012) (2)
Dopamine D2/3 receptor occupancy of apomorphine in the non-human primate brain does not support the existence of two affinity states in vivo (2008) (2)
Imaging of Neurotransmitter Deficits: New Potential Biomarkers for Alzheimer’s Disease? (2006) (2)
Test-retest variability of [C-11]raclopride in rat using PET/MRI (2012) (2)
First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B (2022) (2)
76Br-beta-CBT, a PET tracer for investigating dopamine neuronal uptake. (1995) (2)
Confirmation of fenfluramine effect on 5-HT1B binding of [11C]AZ10419369 using an equilibrium approach (2010) (2)
Validation of SUV as an outcome measure of [C-11]PBR28 in rat using PET/MRI (2012) (2)
In silico studies of ASEM analogues targeting α7-nAChR and experimental verification (2021) (2)
HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER’S DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING (2017) (2)
Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT (2008) (2)
[11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET); Characterization in cynomolgus monkey brain (2008) (2)
Cerebral glucose utilization measured by positron emission tomography. [1-11C]-D-glucose compared with [2-18F]-2-fluoro-2-deoxy-D-glucose. (1991) (1)
A Novel mglur4 compound alleviates motor symptoms in primate models of parkinson's disease (2017) (1)
Development of a fully automated low‐pressure [11C]CO carbonylation apparatus (2020) (1)
Attenuation correction in PET-transmission vs. contour finding in the study of [/sup 11/C]raclopride binding (1993) (1)
Presentation of test measurements with a commercial small animal PET/MR imaging system (2011) (1)
Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [18F]Lu AF10628 (2016) (1)
18th European Symposium on Radiopharmacy and Radiopharmaceuticals (2016) (1)
GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans (2016) (1)
Production method for [11C]-D-glucose labeled in carbon-1 for positron emission tomography of glucose metabolism. (1991) (1)
Effect of amphetamine on dopamine D2 receptor binding in the primate brain with the agonist ligand [11C]MNPA (2005) (1)
5 speaker: How to Image (Tracers). State of the Art and Future Development (2010) (1)
Radiolabeling, preliminary biological evaluation and pet examination in monkey of 5‐methyl‐6‐nitroquipazine — a potential serotonin transporter radioligand (2001) (1)
[18F]MCL-524, an 18F-labeled dopamine D2/D3 receptors agonist radioligand with higher binding signal than [11C]MNPA (2012) (1)
14C-labelling of NNC 756, a new dopamine D1 antagonist (1993) (1)
Production of [11C]Carbon Labelled Flumazenil and L-Deprenyl Using the iMiDEV™ Automated Microfluidic Radiosynthesizer (2022) (1)
A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain (2005) (1)
Preparation and Examination of Labelled Stereoisomers in Vivo by Pet (1995) (1)
On‐line production of 11C‐nitroalkanes and the use of [11C]nitromethane in the synthesis of D‐[1‐11C]glucose (1989) (1)
D-Amphetamine decreases 5-HT1B receptor binding of [11C]AZ10419369 in the monkey brain (2011) (1)
COMT inhibition is a method for avoidance of lipophilic radiometabolites of catechols, exemplified with (S)-[C-11]N-methyl-NNC 01-0259 (2007) (1)
HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER’S DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING (2017) (1)
[18F]6FPWAY — a prospective 5-HT1A receptor radioligand — radiolabeling and pet examination in monkey — comparison with [11C]6FPWAY (2001) (1)
Some New Methods for the Synthesis of Cardiac Neurotransmission PET Radiotracers (1996) (1)
a new, simply labeled antagonist radioligand for imaging brain 5-HT 1A receptors with PET (2007) (1)
New candidate PET radioligands for brain 5-HT1A receptors based on 2,3,4,5,6,7-hexahydro-1{4-[1[4-(2-methoxyphenyl)-piperazinyl]]-2-phenylbutyryl}-m-azepine (RWAY) (2004) (1)
Simplified and accessible [18F]F‐AraG synthesis procedure for preclinical PET (2022) (1)
Scientific Papers (2006) (1)
A novel principle of radiotracer administration in human brain mapping: pet studies on brain uptake and distribution of orally and intravenously administered [11C]vinpocetine (2001) (1)
On the synthesis of 11C-labelled aromatic amino acids (1984) (1)
The metabolism of iodine‐123 labelled 3‐(5‐cyclopropyl‐1,2,4‐oxadiazo‐3‐yl)‐7‐iodo‐5,6‐dihydro‐5‐methyl‐6‐oxo‐4H‐imidazo[1,5‐a][1,4]benzodiazepine (NNC 13–8241) measured in human plasma is only minor (1998) (1)
Kinetic Analysis and Quantification of the Dopamine Transporter in the Nonhuman Primate Brain with (2011) (1)
PET AND AUTORADIOGRAPHY OF BENZODIAZEPINE RECEPTOR BINDING WITH RADIOLABELLED FLUMAZENIL AND RO 15‐4513. (1992) (1)
[18F]Flumazenil for central benzodiazepine receptor imaging and its comparison with [11C] in human brain (2007) (1)
Design and Evaluation of [18F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin Aggregates. (2022) (1)
[11C]N-desmethyl-loperamide, a substrate that selectively images P-glycoprotein function, is trapped in lysosomes (2010) (1)
Clozapine and dopamine D2 blockade. Authors' reply (2002) (1)
Pharmacological Characterization of ( E )- N -(4-Fluorobut-2-enyl)-2 (cid:1) -carbomethoxy-3 (cid:1) -(4 (cid:1) -tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter (2006) (1)
P.1.i.042 A multicenter positron emission tomography study of GABA receptor availability in adults with autism (2017) (1)
Quantitative analysis of dopamine D2 receptor binding in human brain using PET with an agonist radioligand [11C]MNPA (2008) (1)
Striatai and extrastriatal D2-dopamine receptor occupancy during haloperidol and ciozapine treatment (1998) (1)
PET Examination of Central D2 dopamine and 5‐HT2 Receptor Occupancy by Risperidone (1992) (1)
Long-time persistence of D2 dopamine receptor occupancy after discontinuation of haloperidol decanoate (1996) (1)
Synthesis of five benzamide analogs. Comparison with positron emission tomography. (1991) (1)
Comparisons of central benzodiazepine receptor mapping tracers [18F]Flumazenil and [11C]Flumazenil presentation (2006) (1)
AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β-amyloid deposits (2009) (1)
Quantitative analysis of norepinephrine transporter binding in human brain using PET with (S,S)-[18F]FMeNER-D2 (2008) (1)
Development of a central nicotinic acetylcholine receptor radioligand, 5‐methyl‐A‐85380, and postmortem autoradiography in human brain (2001) (1)
Synthesis of [11C]2β-carbomethoxy-3β-(3′-iodo-4′-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography (2000) (1)
Radiosynthesis of [11C]MNPA from the precursor (R)-(−)-2-hydroxy-10,11-acetonide-NPA and a preliminary test–retest PET analysis in monkey brain (2008) (1)
145. Translocator protein (TSPO) as a biomarker of microglia activation: PET imaging using [11C]PBR28 in Parkinson’s disease (2013) (1)
Pharmacological characterization of the interactions of 2-methoxy-N-propylnorapomorphine (MNPA) with D2 and D3 dopamine receptors (2008) (1)
Synthesis of Some11C-Labelled Alkaloids. (1982) (1)
Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism (2012) (1)
11C-labelling of the benzodiazepine antagonist RO 15–1788, in two different positions, and its main metabolite RO 15–3890 (1989) (1)
An HPLC-method for determination of ligand metabolism during PET studies with [11C]metaraminol and [11C]norepinephrine. (1995) (1)
Synthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system. (1995) (1)
In Vivo / In Vitro Characterisation of a Novel MAO-B Inhibitor Radioligand, Fluorine-18 Labeled Deuterated Fluorodeprenyl ( 18 F-Fluorodeprenyl-D 2 ) (2015) (1)
PET determination of robalzotan occupancy of 5-HT1A receptors in the monkey brain (1998) (1)
D2- and 5-HT2 receptor occupancy in “mega-dose” treated schizophrenic patients (1996) (1)
Discovery and labeling of a homochiral high affinity 3,4-diarylpyrazoline as a candidate radioligand for in vivo imaging of cannabinoid type-1 receptors (2008) (1)
Carbon-11 Radiopharmaceuticals - Radiopharmacy Aspects (1992) (1)
Quantification and wavelet-aided parametric imaging of cerebral amyloid using the HRRT PET-system and [18F]AZD4694 (2010) (1)
Dosimetry and whole body distribution of [F-18]PE2I in healthy volunteers (2016) (1)
P-4-61 Autoradiographic comparison of D2- and D3-dopamine receptor localization in the post mortem human brain using [125I]epidepride and [3H]PD 128907 (1995) (1)
Visualizing the central 5-HT1B receptor with PET in rats (2012) (0)
PET D1-Receptor Studies in Schizophrenia (1996) (0)
Correction to “Development of 11C-Labeled ASEM Analogues for Detection of Neuronal Nicotinic Acetylcholine Receptors (α7-nAChR)” (2022) (0)
BRAIN DISTRIBUTION AND BINDING OF [11C]CARIPRAZINE: IN VIVO PET STUDIES IN NON-HUMAN PRIMATES AND WHOLE HEMISPHERE POSTMORTEM AUTORADIOGRAPHIC STUDIES IN HUMAN BRAIN SLICES (2010) (0)
P.3.009 Effects of naltrexone on amphetamine-induced changes in the brain dopamine system (2010) (0)
the binding mode of the PET tracer [ 18 F ] ASEM to a chimera structure of the a 7 nicotinic acetylcholine receptor † (2017) (0)
Synthesis and biological evaluation of a novel radioligand [11C] BIO-1790735 for detection of O-GlcNAcase (OGA) enzyme activity (2022) (0)
P.2.115 PET examinations or thalamic D2 receptors in schizophrenic patients (2003) (0)
D2 and 5-HT2 receptor occupancy in antipsychotic drug treated patients (1994) (0)
The novel mGluR5 radioligand [ 11 C]AZ11696415: Palladium mediated 11 C-cyanation and initial in vivo characterization in the cynomolgus monkey brain using positron emission tomography (PET) (2010) (0)
Effect of amphetamine on dopamine D2 receptors binding in the primate brain with the new agonist ligand [C-11]MNPA (2004) (0)
Detailed mapping of dopamine D2 receptors in the human limbic system using FLB 457 binding analysis in wavelet space (2001) (0)
A new 5‐HT1A receptor radioligand, PB64b — radiolabeling and post‐mortem autoradiography in human brain (2001) (0)
P.1.e.021 In vivo assessment of changes in serotonin release in the non-human primate brain using PET and [11C]AZ10419369 (2010) (0)
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets (2020) (0)
Metabolite pattern of iodinated dopamine transporter radioligand PE2I in rodent and human plasma (1999) (0)
CCDC 1569471: Experimental Crystal Structure Determination (2017) (0)
A new quantitative approach to estimate binding parameters reducing the effect of radiometabolites using three steps of kinetic analysis (2013) (0)
P-13-2 In vivo examination of the Pre- and postsynaptic dopamine neurons in huntington's disease (1996) (0)
Optimal acquisition time window for quantification of dopamine transporter availability with [18F]FE-PE2I in controls and PD patients (2015) (0)
Development of novel C-11- labeled ASEM analogs for detection of neuronal nicotinic acetylcholine receptors (alpha 7-nAChR) (2019) (0)
Synthesis and Preclinical Evaluation of [11C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor. (2022) (0)
Clinical PET-radiopharmaceuticals based on cyclotron based positron emitters other than F-18 (2015) (0)
Invited oral presentations (1997) (0)
Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking (2015) (0)
Two new halogenated analogues of WAY-100635 as potential PET radioligands for the study of 5-HT1A receptors. (2000) (0)
Quantification of [18F]LBT-999 binding to the dopamine transporter in the rhesus monkey brain with the HRRT system (2010) (0)
Evaluation of Two Automated Methods for PET Region of Interest Analysis (2014) (0)
Synthesis of [p-methyl- 11 C]RTI-32 (1999) (0)
S-18-2 Role of serotonin in psychosis (1995) (0)
A Voxelwise Analysis of the Relationship between White Matter Integrity and Impulsivity in Men with Schizophrenia (2004) (0)
S.07.04 Gender differences in the 5-HT1A receptor and serotonin transporter in the human brain: a PET study (2007) (0)
Regional distribution of high and low affinity states of dopamine D2/3 receptor binding in humans: A PET study using [11C]MNPA and [11C]raclopride (2010) (0)
Brain tumour imaging (2010) (0)
Quantification of dopamine transporter in human brain using positron emission tomography with 18F-FE-PE2I (2012) (0)
Synthesis of three F-18 labeled analogues of l -deprenyl for PET studies of monoamine oxidase B (2010) (0)
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [11C]MADAM PET study (2015) (0)
A new quantitative approach for dopamine transporter binding using [11C]PE2I and PET allowing BBB-penetrating radiolabeled metabolite (2011) (0)
[ 18 F]AZD4694 — A new PET radioligand for sensitive detection of β-amyloid deposits (2010) (0)
Abstract # 3081 Impaired cognition and fatigue; the role of sleep and neuroinflammation for non-specific symptoms in allergy (2019) (0)
GSK588045 occupancy of brain 5-HT1A receptors examined using [11C]WAY100635 PET (2010) (0)
Two new C-methyl analogues of WAY-100635-preparation, labeling with carbon-11 and evaluation as PET radioligands for brain 5-HT1A receptors in monkey (2002) (0)
Interleukin -7 (IL-7) Increases Metabolic Thymic and CNS Activity (2012) (0)
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: A template-based analysis (2014) (0)
PET studies in cynomolgous monkeys and whole hemisphere post mortem autoradiographic studies in human brain slices with the dopamine D2/D3 receptor ligand 11C-cariprazine (2010) (0)
Spatial Benzodiazepine Receptor Imaging in the Human Brain (1996) (0)
Automated radiolabeling of [68Ga]Ga-DOTATOC using the iMiDEV™ automated microfluidic radiosynthesizer (2022) (0)
Is the 5-HT2-Receptor a Target for Antipsychotic Drug Action? PET Studies on Dopamine (D2 and Serotonin (5-HT2) Receptor Occupancy in Patients and Healthy Subjects (1995) (0)
Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates (2021) (0)
Clomipramine and the active metabolite, desmethylclomipramine, occupy NET in non-human primate measured by PET (2010) (0)
P.1.g.069 Relationship between dose, plasma concentration and GABA-A receptor occupancy by partial GABA-A receptor modulators (2015) (0)
Astrocytosis precedes amyloid deposition in Alzheimer’s disease Tg2576 APPswe transgenic mice: A multitracer microPET imaging study (2013) (0)
Autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand (2008) (0)
Synthesis of [2-11C]glycine from [11C]nitromethane. (1991) (0)
Synthesis of a novel 18F-labeled radioligand for monoamine oxidase-B and preliminary PET imaging in non-human primate (2018) (0)
Brain tumor imaging: EANM procedure guidelines (2010) (0)
Serotonin 1B receptor density mapping of the human brainstem using positron emission tomography and autoradiography (2021) (0)
The Effect of Metabolic Degradation on Radiotracer Design (1999) (0)
Quantitative analysis of F-FE-PE2I binding to the dopamine transporter in Parkinson’s disease (2015) (0)
Decrease of D1-dopamine receptor binding in the frontal cortex of neuroleptic naive schizophrenic patients measured by PET (1996) (0)
Mapping of the norepinephrine transporter in man using PET with (S,S)-[18F]FMeNER-D2 (2008) (0)
Associations between cognition and serotonin receptor 1B binding in patients with major depressive disorder – A pilot study (2017) (0)
Microdosing of radiolabeled CNS drugs in non-human primates. Assessment of brain exposure and dose dependent effects on brain exposure using positron emission tomography (2012) (0)
Effect of fenfluramine on 5-HT1B binding of [11C]AZ10419369 in the primate brain (2009) (0)
Comparison of [ 18 F]FE-PE2I and [ 18 F]fluorodopa/ PET images in the LPS-induced Parkinsonian rat model (2017) (0)
M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY (2020) (0)
Application of cross-species PET imaging to assess neurotransmitter release in brain (2015) (0)
The metabolite pattern of [123I]beta-CIT determined with a gradient HPLC method. (1995) (0)
510 Neuro-receptor imaging in threedimensions in vivo and in vitro: Application to dopamine and benzodiazepine receptors (1997) (0)
First Evaluation in Humans of [123I]PE2I: A Selective Radioligand for Visualization of the Striatal Dopamine Transporter Density (1999) (0)
Radiolabelling and PET evaluation of the PDE10A PET radioligands, [11C]T-773, [11C]KIT-5 and [11C]KIT-7 in nonhuman primates (NHP) (2013) (0)
The dopamine hypothesis of schizophrenia (2004) (0)
Comparison of performance and workflow of a sequential PET/MR and commercial PET/CT systems (2012) (0)
Altered striatal dopamine levels in Parkinson’s disease VPS35 D620N mutant transgenic aged mice (2020) (0)
PET in the Development of Dopamine D1 Antagonists as New Potential Antipsychotic Drugs (1995) (0)
Title PET-MR and SPECT-MR multimodality probes : development and challenges (2019) (0)
Serotonin 5‐HT1A Receptor Imaging in the Human Brain with Positron‐Emission Tomography: Coordination and the Standardization and Dissemination of Methodology (2001) (0)
Biocompatible branched copolymer nanoparticles prepared by RAFT polymerization as MRI/PET bimodal tracers (2015) (0)
Occupancy of dopamine D2/3 and serotonin 5-HT1A receptors by a novel D3/D2 antipsychotic drug, RGH-188, in nonhuman primate brain: A PET study (2007) (0)
Oral presentations, Tuesday, October 18, 2005 (2005) (0)
P.3.16 Gender differences in the 5-HT1A receptor and serotonin transporter in the human brain: a PET study (2007) (0)
GABA(A) Receptors in Autism - a Multicenter Positron Emission Tomography Study (2015) (0)
Radiofarmaseutika of the preparations were radiojoderade bentsodiatsepinanaloger Science deras anvaendning i diaknostik (1996) (0)
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand , 18 F-Labeled Deuterated (2016) (0)
The automated receptor imaging system (ARIS) for quantitative image processing to estimate binding parameters for dopamine transporter [18F]FE-PE2I studies in non-human primate (NHP) (2014) (0)
PET radioligand [11C]MePPEP binds with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain (2007) (0)
In vitro and in vivo evaluation of 11 CSD 5024 , a novel PET radioligand for human brain imaging of cannabinoid CB 1 receptors ☆ O F (2013) (0)
Norepinephrine transporter occupancy of venlafaxine in patients with major depressive disorder using positron emission tomography and [18F]FMeNER-D2 (2018) (0)
Evaluation of two C-methyl derivatives of C-11-WAY-100635 as potential radioligands for 5-HT1A receptors. (2002) (0)
S-45-2 Distribution of dopamine receptor subtypes in the post-mortem human brain (1996) (0)
Useful in the radiopharmaceutical in the radioiodinated benzodiazepine derivatives and their use in the diagnosis (1996) (0)
Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006 (2006) (0)
Drug development for the CNS using imaging (2006) (0)
Low effect of amphetamine on the binding of the partial dopamine D-1 receptor agonist radioligand [C-11] N-methyl-NNC 01-0259 (2006) (0)
PET and antipsychotic drugs — background (2002) (0)
11 Early clinical development of amyloid-beta specific PET radioligand [18F]AZD4694 (2012) (0)
ABC transporter-dependent brain uptake of the 5-HT 1 B receptor radioligand [ C-11 ] AZ 10419369 (2018) (0)
Quantification of the purinergic P2X7 receptor with [11C]SMW139 improves through correction for brain-penetrating radiometabolites (2022) (0)
P.3.24 Lower 5-HT1A receptor binding in patients with borderline personality disorder: a PET study using [11C]WAY100635 (2008) (0)
New labelled precursors - 11C-alkyl iodides and phosphorous ylides. (1984) (0)
The dopamine hypothesis of schizophrenia : The role of pet (2004) (0)
Occupancy of dopamine D2/D3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA (2008) (0)
COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES (2017) (0)
P.3.02 Molecular imaging of the 5-HT1A receptor and 5-HTT in relation to cognitive functions in man (2008) (0)
A radiopharmaceutical agent useful in benzodiazine radioiodinated benzodiazepine derivatives and their use in the diagnosis (1996) (0)
O-27-5 Autoradiographic localization of 5-HT1A-receptors in the human brain (1996) (0)
Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain (2014) (0)
P.1.06 Limbic dopamine D2-receptor binding and social desirability (2009) (0)
Synthesis of [13C]-Labelled Aldehydes. (1984) (0)
3 In Vivo Imaging of Neurotransmitter Systems with PET (2008) (0)
Pet-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain (1997) (0)
Dopamine transporter in the nigrostriatal system of adolescents with ADHD and neurocognitive performance (2003) (0)
Dopamine transporter binding using [11C]PE2I and PET corrected for tissue heterogeneity and partial volume effect (2007) (0)
P.1.i.027 Quantitative analysis and test-retest reproducibility of a new phosphodiesterase 10A PET radioligand [11C]T-773 in human brain (2015) (0)
S.03.02 PET studies on the dopamine system in vivo (1996) (0)
PET in Neuroscience and Drug Development (2006) (0)
LIGANDS OF THE CORE ACETYLCHOLINE BIOSYNTHESIZING ENZYME, CHOLINE ACETYLTRANSFERASE, AS NOVEL AND POTENTIAL THERAPEUTIC AGENTS AND IN VIVO PET TRACERS FOR EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE (2019) (0)
O-27-9 Reduced D1-dopamine receptor binding in schizophrenia — Relation to psychopathology (1996) (0)
The indigenous gut microbiota modulates the blood–brain barrier in mice (2012) (0)
PET examination of the monkey heart with high specific radioactivity [11C]norepinephrine and [11C]metaraminol. (1995) (0)
5-HT1B receptor imaging in Parkinson's disease with 11C-AZ10419369 and positron emission tomography (2012) (0)
P.3.004 Amphetamine-opioid interactions in the human brain reward system – a PET study using [11C]carfentanil (2012) (0)
Decreased 5‐HT1A binding in mild Alzheimer's disease—A positron emission tomography study (2022) (0)
Increasing the accuracy of in vivo quantification of dopamine-D2/D3 receptor binding in the human brain by partial volume effect correction (2006) (0)
S-52-1 Pet-studies on the dopamine system in vivo (1996) (0)
[18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study (2023) (0)
Effect of ligand mass dose on binding of the β-amyloid specific radioligand [18F]AZD4694 (NAV4694) (2013) (0)
Initial evaluation of [11C]SD5024, a novel PET radioligand for imaging human brain cannabinoid CB1 receptors (2012) (0)
Abstract # 1847 Cross-sectional and longitudinal associations between immune cells in blood and brain – A TSPO PET study in healthy control subjects (2016) (0)
Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans (2023) (0)
(18)F6FPWAY-synthesis and initial investigation as a prospective 5-HT1A receptor radioligand in vivo. (2001) (0)
Automation chemistry with short‐lived positron emitting radionuclides: On‐line 11C‐carboxylation reactions using grignard reagent (2001) (0)
transporter-dependent brain uptake of the 5-HT 1 B receptor radioligand (2014) (0)
A new 18F-labeled ligand for brain 5-HT1A receptors (2004) (0)
PET evaluation of the dopamine D2 receptor agonist (2004) (0)
P.1.e.016 No changes in 5-HT1A receptor and serotonin transporter between phases of the menstrual cycle in healthy women (2007) (0)
Automated system for parametric image analysis in neuroreceptor binding studies with PET (2008) (0)
Distribution of Serotonin Receptor Subtypes in the Post-Mortem Human Brain (1998) (0)
Development of PET Radioligands for the Quantitation of Serotonin Receptors in the Human Brain (1998) (0)
Glutamate 5 receptor availability differences in twins discordant for autism and controls, do shared genetics matter (2023) (0)
Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006 (2006) (0)
Image derived input function using a multivariate analysis method based on pair-wise correlation between PET-image voxels (2012) (0)
Spatial visualization and relative quantification of D2- dopamine receptors in a human post mortem brain hemisphere (1999) (0)
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study (2012) (0)
In vivo correlation of serotonin transporter and 1B receptor availability in the human brain: a PET study (2022) (0)
[I-123]SB 207710 exhibits 5-HT4 receptor-selective binding in monkey brain in vivo. (2000) (0)
Quantitative Analysis of 18 F-PF-06684511, a Novel PET Radioligand for Selective β-secretase 1 Imaging, in Non-human Primate Brain (2018) (0)
Associations between cognition and serotonin 1B receptor availability in healthy volunteers - A [ 11C]AZ10419369 Positron Emission Tomography study. (2022) (0)
P.1.i.028 Brain phosphodiesterase 10A occupancy measured by PET after oral administration of TAK-063, a newly developed phosphodiesterase 10A inhibitor, in human volunteers (2015) (0)
Synthesis and biodistribution of (C-11) labeled irreversible inhibitors of MAO A and B (1985) (0)
P.1.e.030 In vivo monoamine transporter occupancy by venlafaxine and milnacipran in non-human primates (2011) (0)
Synthesis of 11C-labeled (S,S)-CFMME and (R)-OHDMI and their evaluation as candidate radioligands for imaging norepinephrine transporters with PET (2006) (0)
Dopamine transporter binding corrected for tissue heterogeneity and partial volume effect using [11C]PE2I and PET (2006) (0)
Dopamine transporter binding in patients with juvenile myoclonic epilepsy using [11C]PE2I and PET (2010) (0)
No "ceiling effect" observed with the exogenous dopamine agonist apomorphine - A PET study with the dopamine D-2 receptor agonist radioligand [C-11]MNPA and antagonist radioligand [C-11]Raclopride (2006) (0)
Synthesis of [carbonyl‐11C]Way‐100635 (2012) (0)
Method for the routine production of 1 carbon 11 d glucose from carbon 11 ammonium cyanide (1989) (0)
P.1.i.025 Brain PET measurement of phosphodiesterase 10A occupancy by TAK-063, a new phosphodiesterase 10A inhibitor, using [11C]T-773 in nonhuman primates (2015) (0)
Extra-striatal dopamine receptors studied with [125I]epideprideIn VITRO and [[11C]FLB 457in vivo (1995) (0)
Imaging endogenous dopamine occupancy of the D2 receptor in rat brain with [11C]MNPA (2006) (0)
COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES (2017) (0)
The Use of Chiral Recognition in a Bioorganic System for Determination of Optical Purity of Labelled Amino Acids (2010) (0)
D1- and D2-dopamine receptor occupancy during treatment with classical and atypical neurpleptics (1990) (0)
Short Communication Arrestin3 Mediates D 2 Dopamine Receptor Internalization (2009) (0)
The use of [11C]methyl iodide in various N-alkylation reactions. (1984) (0)
P.1.j.040 Social cognition in autism spectrum disorder is associated with brain serotonin transporter availability (2017) (0)
Synthesis of [(CO)-C-11]Raclopride and a Comparison with [(CH3)-C-11]Raclopride in a Monkey PET Study (2015) (0)
FDOPA PET has clinical utility in brain tumour imaging: a proposal for a revision of the recent EANM guidelines - Reply (2007) (0)
Radioiodination of SB 207710 as a prospective radioligand for imaging 5-HT4 receptors in vivo-autoradiography of [125I] SB 207710 against human brain tissue (1999) (0)
P.1.170 A comparative study of serotonin transporter occupancy: In vivo 5-HT reuptake inhibitory potency and serum concentrations of antidepressants in mice (2003) (0)
I-labeled analogues of ACI-80, a prospective molecular imaging biomarker of disease: A whole hemisphere post mortem autoradiography study in human brains obtained from Alzheimer’s disease patients (2012) (0)
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart (2004) (0)
Dr. Nordström and Colleagues Reply (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christer Halldin?

Christer Halldin is affiliated with the following schools:

Christer Halldin's Academic­Influence.com Rankings

Christer Halldin's Degrees

Why Is Christer Halldin Influential?

Christer Halldin's Published Works

Published Works

What Schools Are Affiliated With Christer Halldin?

Christer Halldin's AcademicInfluence.com Rankings